Oryzon Genomics SA stock analysis
Oryzon Genomics SA (0RDB) Share Price & Analysis
0RDB Stock Chart & Stats
- Day’s Range
- EUR 2.24 - EUR 2.39
- 52-Week Range
- EUR 2.24 - EUR 3.50
- Previous Close
- EUR 2.34
- Volume
- N/A
- Average Volume (3M)
- 3,425
- Market Cap
- EUR 191.45M
- Enterprise Value
- EUR 230.85M
- Total Cash (Recent Filing)
- EUR 22.12M
- Total Debt (Recent Filing)
- EUR 7.10M
- Price to Earnings (P/E)
- ―
- Beta
- 0.43
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- -0.06
- Last Dividend Ex-Date
- Mar 15, 2022
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Epigenetic Pipeline
A proprietary epigenetic drug platform gives Oryzon a focused foundation for developing differentiated therapies in areas of high unmet need. Advancing multiple applications across oncology and CNS disorders can broaden long-term opportunity if clinical programs successfully translate into medicines.
Supportive Balance Sheet
Low leverage and expanding assets and equity provide greater financial flexibility than the company’s early-stage profile might otherwise imply. This balance-sheet support can help Oryzon continue funding development programs and absorb operating volatility while limiting near-term dependence on heavy borrowing.
Strong Gross Profit In Revenue Years
Strong gross profit in periods when revenue was generated indicates that Oryzon’s underlying commercial or licensing activity can produce attractive direct economics. If revenue becomes more recurring, this gross-profit profile could support improved operating leverage as development spending is spread across a larger base.
Bears Say
Persistent Operating Losses
Sustained operating and net losses show that Oryzon has not yet converted its research platform into a profitable business. Continued losses can constrain internal reinvestment, increase reliance on external financing, and make long-term earnings power dependent on successful clinical and commercial progress.
Ongoing Cash Burn
Persistent negative operating and free cash flow means the business is not self-funding its research and development activities. Continued cash consumption can reduce financial flexibility over time and may require additional capital before the pipeline generates sustainable operating receipts.
Volatile Revenue Base
Repeated zero-revenue periods indicate that reported income is irregular rather than supported by a dependable recurring base. This volatility makes planning and forecasting more difficult, limits operating leverage, and leaves financial performance highly dependent on non-recurring or intermittent revenue sources.
Oryzon Genomics SA News
0RDB FAQ
What was Oryzon Genomics SA’s price range in the past 12 months?
What is Oryzon Genomics SA’s market cap?
When is Oryzon Genomics SA’s upcoming earnings report date?
How were Oryzon Genomics SA’s earnings last quarter?
Is Oryzon Genomics SA overvalued?
Does Oryzon Genomics SA pay dividends?
What is Oryzon Genomics SA’s EPS estimate?
How many shares outstanding does Oryzon Genomics SA have?
What happened to Oryzon Genomics SA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Oryzon Genomics SA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS and psychiatric diseases. Its product candidates also comprise ORY-3001, an LSD1 inhibitor that is in preclinical development for the treatment of non-oncological diseases; and ORY-4001, a selective HDAC-6 inhibitor for the treatment of neurological disorders, such as Charcot-Marie-Tooth disease (CMT), amyotrophic lateral sclerosis (ALS), and others. It also has collaborations in precision medicine with Columbia University in New York and the Institute of Medical and Molecular Genetics (INGEMM) at La Paz Hospital in Madrid psychometrically characterize patients with mutations in the SetD1A or Shank3 genes; and Cooperative Research and Development Agreement (CRADA) to sponsor several clinical trials. The company was incorporated in 2000 and is based in Cornellà de Llobregat, Spain.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Carlos Manuel Buesa Arjol
- Employees
- 46
- Website
- www.oryzon.com
- Address
- Sant Ferran 74, Cornellà de Llobregat, 08940, ES
Oryzon Genomics SA (0RDB) Earnings & Revenues
0RDB Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |













